의약품 콜드체인 시장 : 1차 포장 유형별, 2차 포장 유형별, 사용법 유형별, 주요 지역별 - 업계 동향과 세계 예측(- 2035년)

COLD CHAIN MARKET FOR PHARMACEUTICALS: OVERVIEW

As per Roots Analysis, the global cold chain market for pharmaceuticals is estimated to grow from USD 6.38 billion in the current year to USD 9.6 billion by 2035, at a CAGR of 3.8% during the forecast period, till 2035.

The market opportunity for cell and gene therapy supply chain software has been distributed across the following segments:

Type of Primary Packaging

• Vials
• Ampoules
• Pre-filled Syringes
• Bags

Type of Secondary Packaging

• Cold Boxes
• Vaccine Carriers
• Insulated Containers

Type of Usability

• Reusable
• Single-use

Key Geographical Regions

• North America
• Europe
• Asia-Pacific
• Middle East and North Africa
• Latin America
• Rest of the World

COLD CHAIN MARKET FOR PHARMACEUTICALS: GROWTH AND TRENDS

Cold chain is a three-fold concept, involving certain aspects that can be co-related to science, technology, and process development. Cold chain solutions aid in maintaining product efficacy and integrity at different stages of the supply chain. Moreover, over the last couple of years, stakeholders have been focused on the development of advanced tools and techniques for monitoring and tracking purposes, particularly real-time monitoring technologies, such as IoT, RFID and blockchain. Additionally, connected cold chain solutions have been observed to offer various advantages over conventional methodologies, including automation across several steps and elimination of human handling errors.

In the near future, connected cold chain solutions are likely to play an important role in overcoming many of the challenges (such as tracking / tracing and delivery time restrictions) that are associated with temperature-sensitive products, thereby minimizing the chances of product spoilage and saving additional costs. Given the ongoing pace of innovation, coupled with technological advancement and continuous efforts of industry players, the cold chain market for pharmaceuticals is expected to witness significant growth in the foreseen future.

COLD CHAIN MARKET FOR PHARMACEUTICALS: KEY INSIGHTS

The report delves into the current state of the cold chain market for pharmaceuticals and identifies potential growth opportunities within the industry. Some key findings from the report include:

1. More than 70 companies currently offer cold chain containers / shippers for the storage and transportation of temperature-sensitive pharmaceutical products.

2. Around 70% of the cold chain container / shipper providers offer passive cold chain packaging solutions; majority of the mid-sized players provide design, track and trace and reuse services for cold chain solutions.

3. Over 65 companies provide data loggers and indicators to monitor crucial parameters, such as temperature, humidity, light, shock, location and status of the cold chain shipment.

4. Owing to the high competition, stakeholders are steadily expanding their capabilities in order to augment their respective service portfolios and comply to the evolving industry benchmarks.

5. A considerable increase in partnership activity has been observed in the recent years; close to 35% of the deals have been inked since 2022, of which, majority (40%) are service agreements.

6. The rising interest in this domain is reflected in the number of mergers and acquisitions reported in the last few years; around 65% of such initiatives were focused on geographical consolidation.

7. Close to 90 patents have been filed / granted for cold chain containers / shippers by industry and non-industry players to protect intellectual property generated within this field.

8. Driven by the expanding pipeline of biologics, and technological advancements in cold chain industry, the market for cold chain packaging products is poised to witness significant growth in foreseeable future.

COLD CHAIN MARKET FOR PHARMACEUTICALS: KEY SEGMENTS

Currently, Vials Occupies the Largest Share of the Cold Chain Market for Pharmaceuticals

Based on the type of primary packaging, the market is segmented into vials, ampoules, pre-filled syringes and bags. At present, vials hold the maximum share of the cold chain market for pharmaceuticals. This trend is unlikely to change in the near future.

Insulated Container is the Fastest Growing Segment of the Cold Chain Market for Pharmaceuticals During the Forecast Period

Based on the type of secondary packaging, the market is segmented into cold boxes, vaccine carriers and insulated containers. At present, cold boxes hold the maximum share of the cold chain market for pharmaceuticals. However, insulated containers are likely to drive the market in the coming decade.

Reusable Packaging is Likely to Dominate the Cold Chain Market for Pharmaceuticals During the Forecast Period

Based on the type of usability, the market is segmented into reusable and single-use. At present, reusable packaging holds the maximum share of the cold chain market for pharmaceuticals. This trend is likely to remain the same in the forthcoming years.

Asia-Pacific Accounts for the Largest Share of the Market

Based on key geographical regions, the market is segmented into North America, Europe, Asia-Pacific, Middle East and North Africa, Latin America, and Rest of the World. Majority share is expected to be captured by players based in Asia-Pacific. It is worth highlighting that, over the years, the market in Europe is expected to grow at a higher CAGR.

Example Players in the Cold Chain Market for Pharmaceuticals

• Cold Chain Technologies
• Cryopak
• CSafe
• EMBALL'ISO
• Intelsius
• Nordic Cold Chain Solutions
• Peli BioThermal
• SEE
• SOFRIGAM
• Sonoco Thermosafe
• Tempack

COLD CHAIN MARKET FOR PHARMACEUTICALS: RESEARCH COVERAGE

• Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the cold chain market for pharmaceuticals, focusing on key market segments, including [A] type of primary packaging, [B] type of secondary packaging, [C] type of usability and [D] key geographical regions.
• Market Landscape 1: A comprehensive evaluation of cold chain container / shipper providers, considering various parameters, such as [A] year of establishment, [B] company size (in terms of the number of employees), [C] location of headquarters, [D] type of cold chain solution, [E] type of product offered, [F] type of product material, [G] type of product packaged, [H] storage temperature and [I] service offered.
• Market Landscape 2: A comprehensive evaluation of data logger providers, considering various parameters, such as [A] year of establishment, [B] company size (in terms of the number of employees), [C] location of headquarters, [D] types of product offered, [E] mode of data transmission, [F] type of data captured, [G] type of pharmaceutical monitored, [H] temperature range.
• Regulatory and Reimbursement Landscape Analysis: A discussion on general regulatory guidelines established and issued by major regulatory bodies for cold chain market for pharmaceuticals. In addition, it includes an insightful analysis, featuring a comparison of the contemporary regulatory scenarios in key geographies across the globe.
• Competitive Benchmarking Analysis: A competitive benchmarking analysis that emphasizes the primary focus areas of cold chain container / shipper providers. This analysis compares their existing capabilities within and beyond their respective peer groups based in North America, Europe and Asia-Pacific. It offers stakeholders insights into potential strategies for achieving a competitive edge in the industry.
• Company Profiles: In-depth profiles of key cold chain container / shipper providers, focusing on [A] company overviews, [B] product portfolio, [C] service portfolio [D] recent developments and [E] an informed future outlook.
• Partnerships and Collaborations: An analysis of partnerships established in this sector, since 2019, based on several parameters, such as [A] year of partnership, [B] type of partnership, [C] application, [D] type of product, [E] geography and [F] most active players (in terms of number of partnerships). In addition, it includes an insightful analysis of the mergers and acquisitions that have been inked between various stakeholders since 2019, based on relevant parameters, such as [A] year of acquisition, [B] type of acquisition, [C] application, [D] type of product, [E] geography, [F] most active players (in terms of number of partnerships), [G] ownership exchange matrix and [H] key value drivers.
• Patent Analysis: Detailed analysis of various patents filed / granted related to cold chain market for pharmaceuticals based on [A] type of patent, [B] publication year, [C] application year, [D] type of organization, [E] patent jurisdiction, [F] CPC symbols, [G] emerging focus areas, [H] leading industry players. It also includes a patent benchmarking analysis and a detailed valuation analysis.
• Upcoming Trends and Future Growth Opportunities: An detailed discussion on the upcoming trends and future opportunities in the cold chain pharmaceutical industry, featuring details on key tools and technologies associated with connected cold chain (artificial intelligence, augmented reality, automation and robotics, big data analytics, block chain technology, cloud computing, internet of things, radio frequency identification tags). It also presents information on real-time monitoring, methods for its integration in cold chain, growth opportunities and cost benefits associated with real-time monitoring in cold chain.
• Market Impact Analysis: The report analyzes various factors such as drivers, restraints, opportunities, and challenges affecting the market growth.

KEY QUESTIONS ANSWERED IN THIS REPORT

• How many companies are currently engaged in this market?
• Which are the leading companies in this market?
• What kind of partnership models are commonly adopted by industry stakeholders?
• What are the factors that are likely to influence the evolution of this market?
• What is the current and future market size?
• What is the CAGR of this market?
• How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

• The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
• Stakeholders can leverage the report to gain a deeper understanding of the competitive dynamics within the market. By analyzing the competitive landscape, businesses can make informed decisions to optimize their market positioning and develop effective go-to-market strategies.
• The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.

ADDITIONAL BENEFITS

• Complimentary PPT Insights Packs
• Complimentary Excel Data Packs for all Analytical Modules in the Report
• 10% Free Content Customization
• Detailed Report Walkthrough Session with Research Team
• Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

• 1.1. Cold Chain Market for Pharmaceuticals
• 1.2. Key Market Insights
• 1.3. Scope of the Report
• 1.4. Research Methodology
• 1.5. Frequently Asked Questions
• 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

• 2.1. Chapter Overview
• 2.2. Research Assumptions
• 2.3. Project Methodology
• 2.4. Forecast Methodology
• 2.5. Robust Quality Control
• 2.6. Key Market Segmentations
• 2.7. Key Considerations
  • 2.7.1. Demographics
  • 2.7.2. Economic Factors
  • 2.7.3. Government Regulations
  • 2.7.4. Supply Chain
  • 2.7.5. COVID Impact / Related Factors
  • 2.7.6. Market Access
  • 2.7.7. Healthcare Policies
  • 2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

• 3.1. Chapter Overview
• 3.2. Market Dynamics
  • 3.2.1. Time Period
    • 3.2.1.1. Historical Trends
    • 3.2.1.2. Current and Forecasted Estimates
  • 3.2.2. Currency Coverage
    • 3.2.2.1. Overview of Major Currencies Affecting the Market
    • 3.2.2.2. Impact of Currency Fluctuations on the Industry
  • 3.2.3. Foreign Exchange Impact
    • 3.2.3.1. Evaluation of Foreign Exchange Rates and Their Impact on Market
    • 3.2.3.2. Strategies for Mitigating Foreign Exchange Risk
  • 3.2.4. Recession
    • 3.2.4.1. Historical Analysis of Past Recessions and Lessons Learnt
    • 3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market
  • 3.2.5. Inflation
    • 3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
    • 3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

• 5.1. Chapter Overview
• 5.2. Introduction to Cold Chain Packaging
• 5.3. Historical Timeline of Cold Chain
• 5.4. Cold Chain Solutions for Pharmaceutical Industry
  • 5.4.1. Cold Chain Packaging Solutions: Containers and Shippers
    • 5.4.1.1. Active Cold Chain Packaging Solutions
    • 5.4.1.2. Passive Cold Chain Packaging Solutions
    • 5.4.1.3. Insulated Cold Chain Packaging Solutions
  • 5.4.2. Cold Chain Monitoring Solutions: Data Loggers
    • 5.4.2.1. Data Loggers
    • 5.4.2.2. Indicators
• 5.5. Applications of Cold Chain in Pharmaceutical Industry
• 5.6. Current Challenges and Future Perspectives

6. OVERALL MARKET LANDSCAPE: COLD CHAIN CONTAINER / SHIPPER PROVIDERS

• 6.1. Chapter Overview
• 6.2. Cold Chain Container / Shipper Providers: Overall Market Landscape
  • 6.2.1. Analysis by Year of Establishment
  • 6.2.2. Analysis by Company Size
  • 6.2.3. Analysis by Location of Headquarters (Region)
  • 6.2.4. Analysis by Location of Headquarters (Country)
  • 6.2.5. Analysis by Type of Cold Chain Solution
  • 6.2.6. Analysis by Type of Product Offered
  • 6.2.7. Analysis by Type of Product Material
  • 6.2.8. Analysis by Type of Product Packaged
  • 6.2.9. Analysis by Storage Temperature
  • 6.2.10. Analysis by Type of Service Offered
  • 6.2.11. Analysis by Company Size and Type of Service Offered

7. OVERALL MARKET LANDSCAPE: DATA LOGGER PROVIDERS

• 7.1. Chapter Overview
• 7.2. Data Logger Providers: Overall Market Landscape
• 7.3. Analysis by Year of Establishment
• 7.4. Analysis by Company Size
• 7.5. Analysis by Location of Headquarters (Region)
• 7.6. Analysis by Location of Headquarters (Country)
• 7.7. Analysis by Type of Product Offered
• 7.8. Analysis by Mode of Data Transmission
• 7.9. Analysis by Type of Data Captured
• 7.10. Analysis by Type of Pharmaceutical Monitored
• 7.11. Analysis by Temperature Range
• 7.12. Analysis by Type of Product Offered and Mode of Data Transmission
• 7.13. Analysis by Type of Product Offered and Type of Data Captured

8. BENCHMARKING ANALYSIS

• 8.1. Chapter Overview
• 8.2. Assumptions and Methodology
• 8.3. Benchmarking Analysis of Cold Chain Container / Shipper Providers
  • 8.3.1. Benchmarking Analysis: Players based in North America (Peer Group I)
  • 8.3.2. Benchmarking Analysis: Players based in Europe (Peer Group II)
  • 8.3.3. Benchmarking Analysis: Large Players based in Asia-Pacific and RoW (Peer Group III)
• 8.4. Concluding Remarks

9. COMPANY PROFILES

• 9.1. Chapter Overview
• 9.2. Cold Chain Technologies
  • 9.2.1. Company Overview
  • 9.2.2. Product Portfolio
  • 9.2.3. Service Portfolio
  • 9.2.4. Recent Developments and Future Outlook
• 9.3. Cryopak
  • 9.3.1. Company Overview
  • 9.3.2. Product Portfolio
  • 9.3.3. Service Portfolio
  • 9.3.4. Recent Developments and Future Outlook
• 9.4. CSafe
  • 9.4.1. Company Overview
  • 9.4.2. Product Portfolio
  • 9.4.3. Service Portfolio
  • 9.4.4. Recent Developments and Future Outlook
• 9.5. EMBALL'ISO
  • 9.5.1. Company Overview
  • 9.5.2. Product Portfolio
  • 9.5.3. Service Portfolio
  • 9.5.4. Recent Developments and Future Outlook
• 9.6. Intelsius
  • 9.6.1. Company Overview
  • 9.6.2. Product Portfolio
  • 9.6.3. Service Portfolio
  • 9.6.4. Recent Developments and Future Outlook
• 9.7. Nordic Cold Chain Solutions
  • 9.7.1. Company Overview
  • 9.7.2. Product Portfolio
  • 9.7.3. Service Portfolio
  • 9.7.4. Recent Developments and Future Outlook
• 9.8. Peli BioThermal
  • 9.8.1. Company Overview
  • 9.8.2. Product Portfolio
  • 9.8.3. Service Portfolio
  • 9.8.4. Recent Developments and Future Outlook
• 9.9. SEE
  • 9.9.1. Company Overview
  • 9.9.2. Product Portfolio
  • 9.9.3. Service Portfolio
  • 9.9.4. Recent Developments and Future Outlook
• 9.10. SOFRIGAM
  • 9.10.1. Company Overview
  • 9.10.2. Product Portfolio
  • 9.10.3. Service Portfolio
  • 9.10.4. Recent Developments and Future Outlook
• 9.11. Sonoco Thermosafe
  • 9.11.1. Company Overview
  • 9.11.2. Product Portfolio
  • 9.11.3. Service Portfolio
  • 9.11.4. Recent Developments and Future Outlook
• 9.12. Tempack
  • 9.12.1. Company Overview
  • 9.12.2. Product Portfolio
  • 9.12.3. Service Portfolio
  • 9.12.4. Recent Developments and Future Outlook
• 9.13. Other Leading Players
  • 9.13.1. Almac
  • 9.13.2. B Medical Systems
  • 9.13.3. BioLife Solutions
  • 9.13.4. CRS Mobile Cold Storage
  • 9.13.5. Desert Valley Tech
  • 9.13.6. Dubai Instruments
  • 9.13.7. Envirotainer
  • 9.13.8. Global Cold Chain Solutions (Headquartered in Australia)
  • 9.13.9. Global Cold Chain Solutions (Headquartered in Singapore)
  • 9.13.10. Klinge
  • 9.13.11. Krautz-temax
  • 9.13.12. Meds2go
  • 9.13.13. phasetwo
  • 9.13.14. Polar Tech Industries
  • 9.13.15. Skycell
  • 9.13.16. UPS Healthcare

10. PARTNERSHIPS AND COLLABORATIONS

• 10.1. Chapter Overview
• 10.2. Partnership Models
• 10.3. Cold Chain for Pharmaceuticals: Partnerships and Collaborations
  • 10.3.1. Analysis by Year of Partnership
  • 10.3.2. Analysis by Type of Partnership
  • 10.3.3. Analysis by Year and Type of Partnership
  • 10.3.4. Analysis by Application Area
  • 10.3.5. Analysis by Type of Product / Technology Targeted
  • 10.3.6. Analysis by Geography
    • 10.3.6.1. Local and International Agreements
    • 10.3.6.2. Intercontinental and Intracontinental Agreements
  • 10.3.7. Most Active Players: Analysis by Number of Partnerships
• 10.4. Cold Chain for Pharmaceuticals: Acquisitions
  • 10.4.1. Analysis by Year of Acquisition
  • 10.4.2. Analysis by Type of Acquisition
  • 10.4.3. Analysis by Year and Type of Acquisition
  • 10.4.4. Analysis by Application Area
  • 10.4.5. Analysis by Type of Product / Technology Targeted
  • 10.4.6. Analysis by Geography
    • 10.4.6.1. Local and International Agreements
    • 10.4.6.2. Intercontinental and Intracontinental Agreements
  • 10.4.7. Ownership Change Matrix
  • 10.4.8. Analysis by Key Value Drivers

11. PATENT ANALYSIS

• 11.1. Chapter Overview
• 11.2. Scope and Methodology
• 11.3. Cold Chain for Pharmaceuticals: Patent Analysis
  • 11.3.1. Analysis by Type of Patent
  • 11.3.2. Analysis by Publication Year
  • 11.3.3. Analysis by Type of Patent and Publication Year
  • 11.3.4. Analysis by Application Year
  • 11.3.5. Analysis by Type of Organization
  • 11.3.6. Analysis by Patent Jurisdiction
  • 11.3.7. Analysis by CPC Symbols
  • 11.3.8. Analysis by Emerging Focus Area
  • 11.3.9. Leading Industry Players: Analysis by Number of Patents
• 11.4. Cold Chain for Pharmaceuticals: Patent Benchmarking Analysis
  • 11.4.1. Analysis by Patent Characteristics
    • 11.4.1.1. Cold Chain Technologies and Ember LifeSciences
    • 11.4.1.2. Other Leading Patent Assignees
• 11.5. Patent Valuation Analysis

12. REGULATORY RECOMMENDATIONS AND GUIDELINES

• 12.1. Chapter Overview
• 12.2. Regulatory Guidelines Issued by International Authorities
  • 12.2.1. World Health Organization (WHO)
  • 12.2.2. International Air Transport Association (IATA)
  • 12.2.3. International Safe Transit Association (ISTA)
• 12.3. Regulatory Guidelines Issued by Regional Authorities
  • 12.3.1. Regulatory Guidelines for Cold Chain Management in the US
    • 12.3.1.1. United States Food and Drug Administration (USFDA)
  • 12.3.2. United States Pharmacopeia (USP)
  • 12.3.3. Regulatory Guidelines for Cold Chain Management in Canada
    • 12.3.3.1. Health Canada
  • 12.3.4. Regulatory Guidelines for Cold Chain Management in Europe
    • 12.3.4.1. European Medicine Agency
• 12.4. Recommendations for Different Steps of Cold Chain
• 12.5. Comparative Analysis of Regulatory Authorities

13. UPCOMING TRENDS AND FUTURE GROWTH OPPORTUNITIES

• 13.1. Chapter Overview
• 13.2. Connected Cold Chain: Key Tools and Technologies
  • 13.2.1. Artificial Intelligence
  • 13.2.2. Augmented Reality
  • 13.2.3. Automation and Robotics
  • 13.2.4. Big Data Analytics
  • 13.2.5. Block Chain Technology
  • 13.2.6. Cloud Computing
  • 13.2.7. Internet of Things
  • 13.2.8. Radio Frequency Identification (RFID) Tags
• 13.3. Connected Cold Chain: Future Growth Opportunities
• 13.4. Real-Time Monitoring: An Application of Connected Cold Chain Solutions
  • 13.4.1. Methods for Integration of Real-Time Monitoring in Cold Chain
    • 13.4.1.1. RFID Based Real-Time Monitoring
    • 13.4.1.2. Blockchain And IoT Based Real-Time Monitoring
  • 13.4.2. Growth Opportunities for Real-Time Monitoring in Connected Cold Chain
  • 13.4.3. Cost Benefits of Real-Time Monitoring in Cold Chain

14. MARKET IMPACT ANALYSIS: DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES

• 14.1. Chapter Overview
• 14.2. Market Drivers
• 14.3. Market Restraints
• 14.4. Market Opportunities
• 14.5. Market Challenges
• 14.6. Conclusion

15. COLD CHAIN MARKET FOR PHARMACEUTICALS

• 15.1. Chapter Overview
• 15.2. Assumptions and Methodology
• 15.3. Global Cold Chain Market for Pharmaceuticals, Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 15.3.1. Scenario Analysis
• 15.4. Key Market Segmentations
• 15.5. Dynamic Dashboard

16. COLD CHAIN MARKET FOR PHARMACEUTICALS, BY TYPE OF PRIMARY PACKAGING

• 16.1. Chapter Overview
• 16.2. Key Assumptions and Methodology
• 16.3. Cold Chain for Pharmaceuticals: Analysis by Type of Primary Packaging (2019, current year and 2035)
  • 16.3.1. Vials: Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 16.3.2. Ampoules: Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 16.3.3. Pre-filled Syringes: Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 16.3.4. Bags: Historical Trends (since 2019) and Forecasted Estimates (till 2035)
• 16.4. Data Triangulation and Validation

17. COLD CHAIN MARKET FOR PHARMACEUTICALS, BY TYPE OF SECONDARY PACKAGING

• 17.1. Chapter Overview
• 17.2. Key Assumptions and Methodology
• 17.3. Cold Chain for Pharmaceuticals: Analysis by Type of Secondary Packaging (2019, current year and 2035)
  • 17.3.1. Cold Boxes: Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 17.3.2. Vaccine Carriers: Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 17.3.3. Insulated Containers: Historical Trends (since 2019) and Forecasted Estimates (till 2035)
• 17.4. Data Triangulation and Validation

18. COLD CHAIN MARKET FOR PHARMACEUTICALS, BY TYPE OF USABILITY

• 18.1. Chapter Overview
• 18.2. Key Assumptions and Methodology
• 18.3. Cold Chain for Pharmaceuticals: Analysis by Type of Usability (2019, current year and 2035)
  • 18.3.1. Reusable Containers / Shippers: Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 18.3.2. Single-use Containers / Shippers: Historical Trends (since 2019) and Forecasted Estimates (till 2035)
• 18.4. Data Triangulation and Validation

19. COLD CHAIN MARKET FOR PHARMACEUTICALS, BY KEY GEOGRAPHICAL REGIONS

• 19.1. Chapter Overview
• 19.2. Key Assumptions and Methodology
• 19.3. Cold Chain for Pharmaceuticals: Analysis by Key Geographical Regions (2019, current year and 2035)
  • 19.3.1. North America: Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 19.3.2. Europe: Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 19.3.3. Asia-Pacific: Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 19.3.4. Middle East and North America: Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 19.3.5. Latin America: Historical Trends (since 2019) and Forecasted Estimates (till 2035)
  • 19.3.6. Rest of the World: Historical Trends (since 2019) and Forecasted Estimates (till 2035)
• 19.4. Data Triangulation and Validation

20. CONCLUSION

21. EXECUTIVE INSIGHTS

• 21.1. Chapter Overview
• 21.2. EMBALL'ISO
  • 21.2.1. Company Snapshot
  • 21.2.2. Interview Transcript
• 21.3. Tower Cold Chain
  • 21.3.1. Company Snapshot
  • 21.3.2. Interview Transcript

22. APPENDIX 1: TABULATED DATA

23. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS